AVITA Medical, Inc. Stock Australian S.E.

Equities

AVH

AU000000AVH4

Biotechnology & Medical Research

Delayed Australian S.E. 02:10:52 2024-04-24 am EDT 5-day change 1st Jan Change
2.77 AUD +2.97% Intraday chart for AVITA Medical, Inc. -10.36% -35.43%
Sales 2024 * 115M 74.66M Sales 2025 * 165M 107M Capitalization 341M 222M
Net income 2024 * -56M -36.42M Net income 2025 * -17M -11.06M EV / Sales 2024 * 2.8 x
Net cash position 2024 * 19.8M 12.87M Net cash position 2025 * 1.85M 1.21M EV / Sales 2025 * 2.05 x
P/E ratio 2024 *
-6.41 x
P/E ratio 2025 *
-34.7 x
Employees 207
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.34%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on AVITA Medical, Inc.

1 day+2.97%
1 week-10.36%
Current month-44.04%
1 month-44.38%
3 months-41.19%
6 months-13.71%
Current year-35.43%
More quotes
1 week
2.66
Extreme 2.66
2.89
1 month
2.66
Extreme 2.66
5.06
Current year
2.66
Extreme 2.66
5.62
1 year
2.66
Extreme 2.66
6.27
3 years
1.28
Extreme 1.28
6.27
5 years
1.28
Extreme 1.28
17.30
10 years
0.92
Extreme 0.92
17.30
More quotes
Date Price Change Volume
24-04-24 2.77 +2.97% 281,858
24-04-23 2.69 -3.24% 545,617
24-04-22 2.78 -0.71% 567,535
24-04-19 2.8 -5.08% 714,835
24-04-18 2.95 -4.53% 687,270

Delayed Quote Australian S.E., April 24, 2024 at 02:10 am EDT

More quotes
AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
13.21 AUD
Average target price
40.61 AUD
Spread / Average Target
+207.46%
Consensus